NCT00040599View on ClinicalTrials.gov

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2000

Study Completion Date

January 31, 2004

Conditions
Colorectal CancerColon CancerRectal CancerColorectal NeoplasmsColorectal CarcinomaColorectal Tumor
Interventions
DRUG

hMN14 (labetuzumab)

Trial Locations (10)

15213

University of Pittsburgh Cancer Institute, Pittsburgh

20010

Washington Hospital Center, Washington D.C.

33744

Bay Pines VA Medical Center, St. Petersburg

92658

Hoag Cancer Center, Newport Beach

98101-2799

Virginia Mason Medical Center, Seattle

D99437

Zentralklinik Bad Berka, Bad Berka

D-01307

University Hospital Dresden, Dresden

Unknown

University of Szeged Medical Center, Szeged

S-75185

Uppsala University Hospital, Uppsala

CH-1011

Centre Pluridisciplinaire d'Oncologie, Lausanne

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00040599 - Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | Biotech Hunter | Biotech Hunter